<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01255709</url>
  </required_header>
  <id_info>
    <org_study_id>API-E004-CL-B3</org_study_id>
    <nct_id>NCT01255709</nct_id>
  </id_info>
  <brief_title>Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS</brief_title>
  <official_title>CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS, A Randomized, Evaluator-Blind, Single-Dose, Three Arm, Crossover,PK Study in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amphastar Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amphastar Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine
      Inhalation Aerosol USP, an HFA134a propelled Metered Dose Inhaler (MDI) (E004), using a
      stable isotope deuterium-labeled epinephrine (epinephrine-d3) to differentiate the
      administered drug from the endogenous epinephrine, in healthy male and female adult
      volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study is designed to complement and expand the previous PK studies, API-E004-CL-B
      and API-E004-CL-B2, with emphasis on lower E004 dose strengths (at 90 and 100 mcg per
      inhalation), for a more thorough evaluation of the E004 PK profiles. Safety of E004 will also
      be evaluated, under augmented dose conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics including maximum concentration and area under the curve</measure>
    <time_frame>-30, 2, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 45, 60, 90, 120, 240 and 360 min postdose.</time_frame>
    <description>Samples will be analyzed with an established LC/MS/MS method, with a quantitative detection limit of 0.02 ng/mL, for both epinephrine-d3 and epinephrine-h3.
Mean Maximum concentration of epinephrine (Cmax for epinephrine)
Mean Area Under the Curve (AUC) for epinephrine
Time to maximum concentration (tmax) and Half life of the drug (t1/2)
Epinephrine concentrations versus time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>within 30 min predose, at 30, 60 and 360 min postdose</time_frame>
    <description>Systolic and Diastolic Blood pressure and heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead Electrocardiogram (ECG)</measure>
    <time_frame>within 30 min pre-dose, and at 15 and 120 min post-dose</time_frame>
    <description>12 lead ECG (Routine and QT/QTc intervals)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Telemetry ECG</measure>
    <time_frame>within 30 min pre-dose, and during the initial 5 min post-dose</time_frame>
    <description>Telemetry recording of heart rate</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Arm T1 Primatene Mist HFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C Primatene Mist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm T2 Primatene Mist HFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm T1: Primatene Mist HFA</intervention_name>
    <description>epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes</description>
    <arm_group_label>Arm T1 Primatene Mist HFA</arm_group_label>
    <other_name>epinephrine inhalation aerosol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm T2: Primatene Mist HFA</intervention_name>
    <description>epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes</description>
    <arm_group_label>Arm T2 Primatene Mist HFA</arm_group_label>
    <other_name>epinephrine inhalation aerosol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)</intervention_name>
    <description>epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes</description>
    <arm_group_label>Arm C Primatene Mist</arm_group_label>
    <other_name>epinephrine inhalation aerosol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy at screening;

          -  Body weight ≥ 50 kg for men and ≥ 45 kg for women;

          -  Sitting blood pressure ≤ 135/90 mmHg;

          -  Demonstrating negative hIV, HBsAG and DCV-Ab screen tests;

          -  Women of child-bearing potential must be non-pregnant, non-lactating, and practicing a
             clinically acceptable form of birth control;

          -  Properly consented

          -  Other criteria apply

        Exclusion Criteria:

          -  A smoking history of ≥10 pack-years, or having smoked within 6 months prior to
             Screening;

          -  Upper respiratory tract infections within 2 wk, or lower respiratory tract infection
             within 4 wk, prior to Screening;

          -  Any current or recent respiratory conditions that might significantly affect
             pharmacodynamic response to the study drugs;

          -  Known intolerance or hypersensitivity to the study MDI ingredients;

          -  Having been on other investigational drug/device studies, or donated blood, in the
             last 30 days prior to Screening;

          -  Other criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Amphastar Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amphastar Study Site 1</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pinnas JL, Schachtel BP, Chen TM, Roseberry HR, Thoden WR. Inhaled epinephrine and oral theophylline-ephedrine in the treatment of asthma. J Clin Pharmacol. 1991 Mar;31(3):243-7.</citation>
    <PMID>2019665</PMID>
  </reference>
  <reference>
    <citation>Hendeles L, Marshik PL, Ahrens R, Kifle Y, Shuster J. Response to nonprescription epinephrine inhaler during nocturnal asthma. Ann Allergy Asthma Immunol. 2005 Dec;95(6):530-4.</citation>
    <PMID>16400891</PMID>
  </reference>
  <reference>
    <citation>Warren JB, Doble N, Dalton N, Ewan PW. Systemic absorption of inhaled epinephrine. Clin Pharmacol Ther. 1986 Dec;40(6):673-8.</citation>
    <PMID>3780129</PMID>
  </reference>
  <reference>
    <citation>Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med. 2000 Jun;94 Suppl B:S3-9.</citation>
    <PMID>10919679</PMID>
  </reference>
  <reference>
    <citation>Dickinson BD, Altman RD, Deitchman SD, Champion HC. Safety of over-the-counter inhalers for asthma: report of the council on scientific affairs. Chest. 2000 Aug;118(2):522-6.</citation>
    <PMID>10936150</PMID>
  </reference>
  <reference>
    <citation>Simons FE, Gu X, Johnston LM, Simons KJ. Can epinephrine inhalations be substituted for epinephrine injection in children at risk for systemic anaphylaxis? Pediatrics. 2000 Nov;106(5):1040-4.</citation>
    <PMID>11061773</PMID>
  </reference>
  <reference>
    <citation>Kushner DJ, Baker A, Dunstall TG. Pharmacological uses and perspectives of heavy water and deuterated compounds. Can J Physiol Pharmacol. 1999 Feb;77(2):79-88. Review.</citation>
    <PMID>10535697</PMID>
  </reference>
  <reference>
    <citation>Bondesson E, Friberg K, Soliman S, Löfdahl CG. Safety and efficacy of a high cumulative dose of salbutamol inhaled via Turbuhaler or via a pressurized metered-dose inhaler in patients with asthma. Respir Med. 1998 Feb;92(2):325-30.</citation>
    <PMID>9616533</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2010</study_first_submitted>
  <study_first_submitted_qc>December 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2010</study_first_posted>
  <disposition_first_submitted>February 18, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>February 18, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 17, 2016</disposition_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>shortness of breath</keyword>
  <keyword>wheezing</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

